Gliclazide extended-release tablets are hypoglycemic drugs, which itself has no significant side effects on the kidneys, but abnormal renal function will affect the excretion of the product, resulting in increased blood concentration, so patients with renal disease should be used under the guidance of a physician in strict compliance with the doctor’s instructions, and it should be prohibited for people with severe renal insufficiency. The main ingredient of gliclazide extended-release tablets is gliclazide, which can be used for the treatment of type 2 diabetes mellitus in adults whose blood glucose level cannot be controlled by dietary therapy or exercise therapy and weight reduction alone. It should be contraindicated in people with known hypersensitivity to gliclazide or one of the excipients and other sulfonylureas, sulfonamides, diabetic ketoacidosis, and lactating women. Common adverse reactions to this product include hypoglycemia and gastrointestinal dysfunction. Gliclazide extended-release tablets should be used in strict accordance with medical advice.